Sarah Lynam, MD, discusses the clinical applicability of mirvetuximab soravtansine and trastuzumab deruxtecan in recurrent ovarian cancer.
Sarah Lynam, MD
Advertisement
Sarah Lynam, MD, is an assistant professor in the Division of Gynecologic Oncology in the Department of Reproductive Biology at Case Western Reserve University School of Medicine and an attending physician in the Division of Gynecologic Oncology at the Seidman Cancer Center at the University Hospitals Cleveland Medical Center in Ohio.
Articles by Sarah Lynam, MD
Sarah Lynam, MD, details key efficacy data from the phase 2 DESTINY-PanTumor02 trial, evaluating trastuzumab deruxtecan in HER2-expressing solid tumors.
Sarah Lynam, MD, highlights the importance of folate receptor–alpha expression testing to inform treatment decision-making in patients with ovarian cancer.
Sarah Lynam, MD, discusses the significance and implications of mirvetuximab soravtansine for the treatment of patients with ovarian cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
4
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
5